Who is this protocol a good fit for?

Anyone trying to understand what tesamorelin or Egrifta is actually approved for. Anyone who has seen tesamorelin marketed for general fat loss or anti-aging and wants the approved-use boundary. Patients or caregivers preparing questions for a prescriber. Readers comparing tesamorelin to unregulated GH-secretagogue “research peptides”

What are the cautions for this protocol?

Educational only, not medical advice; any decision about a prescription medication belongs with a licensed prescriber.. The FDA approval covers HIV-associated lipodystrophy specifically, not general fat loss, muscle gain, or anti-aging.. The label carries a malignancy caution standard for GH-axis drugs; discuss personal risk factors with a prescriber.

← Home / Peptides / YourProtocol / Tesamorelin (Egrifta): Evidence and Safety

Peptides Peptides

Tesamorelin (Egrifta): Evidence and Safety

Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog that is FDA-approved, as Egrifta, specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Using it for general fat loss, muscle gain, or anti-aging in people without that condition is off-label and not what its approval is based on, despite the “GH secretagogue for longevity” framing it gets in biohacker circles.

💊

YourProtocol

YourProtocol Research

In-house · Synthesized from the cited primary sources

Daily time

5 min

Difficulty

Beginner

Sources

What the evidence says

What it is

Understand the mechanism

A GHRH analog: it stimulates the body's own pituitary gland to release growth hormone, rather than supplying growth hormone directly.

This indirect mechanism is why tesamorelin is discussed alongside other GH-axis peptides, though its approval is narrow.

FDA approval record; Theratechnologies

For this step

No product needed

Evidence tier: A (for HIV-associated lipodystrophy only)

See what the approval actually covers

FDA-approved in 2010 (Egrifta) for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; reformulated as Egrifta SV (2019) and Egrifta WR (approved March 25, 2025) for the same indication.

The evidence tracks the approved indication, not the broader “GH secretagogue for longevity” use it gets marketed for.

FDA approval record; Theratechnologies (manufacturer)

For this step

No product needed

Legal status

Know what is and is not approved

FDA-approved, but only for HIV-associated lipodystrophy. Using tesamorelin for general fat loss, muscle gain, or anti-aging in people without that condition is off-label.

The approval is condition-specific; it is not a general-use GH-axis approval.

FDA approval record

For this step

No product needed

Safety

Know the labeled risks

Labeled risks include injection-site reactions, joint pain, and a theoretical concern around GH-axis stimulation (glucose intolerance); the label carries caution around malignancy given GH's growth-promoting mechanism, standard for GH-axis drugs. Off-label or compounded “tesamorelin” for cosmetic or longevity use bypasses this safety monitoring.

These are the labeled risks for the approved population; off-label use in a different population has not been evaluated the same way.

FDA labeling

For this step

No product needed

What it is

Tesamorelin stimulates the body's own pituitary gland to release growth hormone, rather than supplying growth hormone directly. This page is informational: it reports what tesamorelin is, what its FDA approval actually covers, and where the evidence stops. It is not instructions for use.

Why it works▼

The FDA first approved tesamorelin in 2010 (as Egrifta) specifically for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; it was reformulated as Egrifta SV in 2019, and a further reformulation, Egrifta WR, received FDA approval on March 25, 2025 for the same indication with a simpler weekly-reconstitution regimen. This is real, current regulatory history from the manufacturer, Theratechnologies. The evidence tier is Tier A, but only for that specific approved indication; using tesamorelin for general fat loss, muscle gain, or anti-aging in people without HIV-associated lipodystrophy is off-label and does not rest on the same trial evidence. Andrew Huberman's Huberman Lab episode on peptide therapeutics confirms tesamorelin's FDA approval is specifically for HIV-associated lipodystrophy, matching the Tier A framing here.

The evidence

Sources 1

Primary sources behind this page, cited straight to the source: peer-reviewed papers and reporting. Select any to view it here.

Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (confirms tesamorelin's FDA approval for HIV-associated lipodystrophy)

Article · hubermanlab.com

Source viewer

Loading the first source…

Is this for you?

Good fit if

Anyone trying to understand what tesamorelin or Egrifta is actually approved for
Anyone who has seen tesamorelin marketed for general fat loss or anti-aging and wants the approved-use boundary
Patients or caregivers preparing questions for a prescriber
Readers comparing tesamorelin to unregulated GH-secretagogue “research peptides”

Cautions

Educational only, not medical advice; any decision about a prescription medication belongs with a licensed prescriber.
The FDA approval covers HIV-associated lipodystrophy specifically, not general fat loss, muscle gain, or anti-aging.
The label carries a malignancy caution standard for GH-axis drugs; discuss personal risk factors with a prescriber.

Common questions

Is tesamorelin FDA-approved?▾

Yes, as Egrifta (now Egrifta WR), but only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. General fat-loss, muscle-gain, or anti-aging use is off-label.

Can tesamorelin be used for general anti-aging or fat loss?▾

That use is off-label. Its FDA approval and supporting trial evidence are specific to HIV-associated lipodystrophy, not general longevity or fat-loss use.

What's the newest approved version of tesamorelin?▾

Egrifta WR, approved by the FDA on March 25, 2025, a reformulation with a simpler weekly-reconstitution regimen for the same HIV-associated lipodystrophy indication.

Get the next protocol first

New expert protocols and evidence updates, cited to the source. No spam; unsubscribe anytime.

Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.

Tesamorelin (Egrifta): Evidence and Safety

Read the evidence

Read it